Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Niclosamide - Entero Therapeutics

Next Previous
X
Search
Drug Profile

Niclosamide - Entero Therapeutics

Alternative Names: FW 424; FW-1022; FW-420; FW-CD; FW-COV; FW-ICI-AC; FW-UC; FW-UP; micronized niclosamide - Entero Therapeutics

Latest Information Update: 21 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator First Wave Bio
  • Developer Entero Therapeutics
  • Class Anthelmintics; Anti-inflammatories; Antibacterials; Antineoplastics; Antivirals; Benzamides; Chlorophenols; Nitrobenzenes; Skin disorder therapies; Small molecules
  • Mechanism of Action Autophagy stimulants; Mitochondrial oxidative phosphorylation uncouplers; MTOR protein inhibitors; NF-kappa B inhibitors; Notch signalling pathway inhibitors; STAT3 transcription factor inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ulcerative proctitis; Ulcerative proctosigmoiditis
  • Preclinical Crohn's disease; Gastroenteritis; Ulcerative colitis
  • Discontinued Gastrointestinal disorders

Most Recent Events

  • 16 May 2024 First Wave Biopharma is now called Entero Therapeutics
  • 31 Dec 2023 First Wave Biopharma has patent protection for niclosamide in COVID-19 gastrointestinal infections in USA and Patent Cooperation Treaty (PCT) (First Wave BioPharma SEC 2024)
  • 27 Dec 2023 Undisclosed company enters into non-binding term sheet agreement to acquire Niclosamide from First Wave Biopharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top